Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision medicine company dedicated to transforming the drug discovery process. Headquartered in Cambridge, Massachusetts, the company focuses on combining advanced computational and experimental technologies to develop life-changing therapies. Since its inception in 2016, Relay Therapeutics has been pioneering a new paradigm in the pharmaceutical industry by placing protein motion at the core of drug discovery.
The company's flagship platform, Dynamo™, integrates cutting-edge computational and experimental approaches to target protein structures that are either intractable or inadequately addressed by current therapies. This platform has enabled the development of multiple promising drug candidates, particularly in the fields of precision oncology and genetic diseases. Key product candidates include RLY-4008, RLY-2608, and GDC-1971 (formerly RLY-1971).
Relay Therapeutics' recent corporate highlights include significant advancements in its RLY-2608 program, aimed at treating patients with PI3Kα-mutated HR+/HER2- breast cancer. The company's development pipeline has been robust, with expectations to disclose innovative programs later this year.
Financially, as of March 31, 2024, Relay Therapeutics reported cash, cash equivalents, and investments totaling approximately $749.6 million. This financial stability is projected to fund the company's operations into the second half of 2026. The company’s revenue for Q1 2024 was $10 million, primarily derived from milestone payments under a collaboration agreement with Genentech, Inc.
Relay Therapeutics has also established strategic partnerships with notable entities such as Pfizer, Nextech, and Genentech, enhancing its capability to advance its clinical and preclinical programs. The company’s innovative approach has attracted significant investment from third-party ventures, including GV (formerly Google Ventures) and Alexandria Venture Investments.
Relay Therapeutics continues to push the boundaries of what’s possible in drug discovery, aiming to improve the lives of millions of patients through precision medicine.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming healthcare conferences. The first is a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 9:30 a.m. ET. Following this, Relay will join a panel discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. Both events will be webcast live, and viewers can access them via the Investors & Media page on Relay's website. Archived replays will be available for 30 days post-event.
Relay Therapeutics (Nasdaq: RLAY) has commenced a first-in-human trial for RLY-2608, a pan-mutant PI3Kα inhibitor, dosing its first patient with advanced solid tumors harboring PIK3CA mutations. Simultaneously, it has initiated expansion cohorts for RLY-4008, a selective FGFR2 inhibitor, targeting patients with FGFR2-altered cancers. Both trials aim to evaluate the drugs' safety, tolerability, and efficacy, expanding upon promising prior data. With a robust pipeline and strong financial position, the company is well-positioned to advance its clinical programs and address significant unmet medical needs.
Relay Therapeutics (Nasdaq: RLAY) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 a.m. ET. Interested parties can access the live webcast through the company's website, with an archived replay available for 30 days post-presentation. Relay Therapeutics specializes in precision medicine, utilizing its innovative Dynamo™ platform to advance drug discovery aimed at targeted oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) presented promising preclinical data for RLY-2608, a novel allosteric PI3Kα inhibitor, at the 2021 San Antonio Breast Cancer Symposium. The data highlighted the compound's ability to synergize with standard therapies like fulvestrant and abemaciclib, leading to significant tumor regression in breast cancer models. RLY-2608 is designed to selectively target PIK3CA mutant tumors while minimizing toxicity. A first-in-human clinical trial is expected to commence in the first half of 2022, pending FDA approval.
Relay Therapeutics, Inc. (Nasdaq: RLAY) reported third quarter 2021 results, highlighting key advancements in clinical trials and financial performance. The company disclosed interim clinical data for RLY-4008, a selective FGFR2 inhibitor, indicating significant potential. Relay raised $402 million through a follow-on public offering, enhancing its financial position. However, the net loss increased to $60.8 million compared to $36.1 million a year earlier. Cash and investments totaled approximately $616.5 million, expected to fund operations at least until 2025.
Relay Therapeutics (Nasdaq: RLAY) has announced that it will report its third quarter 2021 financial results on November 10, 2021, after market closure. No accompanying teleconference will be held. The company specializes in precision medicine and is focused on enhancing drug discovery, particularly in targeted oncology and genetic diseases, using its proprietary Dynamo™ platform that integrates advanced computational and experimental technologies.
Mark Murcko has been appointed as a Strategic Advisor and Board Member at Octant, bringing over 30 years of biotech experience. Previously, he served as CSO at Dewpoint Therapeutics. Murcko will aid Octant in scaling its chemistry platform and drug discovery process. The company focuses on advancing therapeutics by integrating high-throughput biology and computation since its lab opened in 2019. Octant has established several therapeutic programs showing efficacy in pre-clinical models, positioning itself for significant growth.
Relay Therapeutics (Nasdaq: RLAY) announced a public offering of 13,207,547 shares of its common stock at $26.50 per share, expecting gross proceeds of approximately $350 million before expenses. The underwriters have a 30-day option to purchase an additional 1,981,132 shares.
The offering is set to close around October 15, 2021. This funding aims to enhance Relay's drug discovery processes in targeted oncology and genetic diseases through its advanced Dynamo™ platform.
Relay Therapeutics (Nasdaq: RLAY) has initiated a public offering of $350 million in common stock, with a 30-day option for underwriters to purchase an additional 15%. The share sale is underwritten by Goldman Sachs, J.P. Morgan, Cowen, and Guggenheim Securities. The offering is subject to market conditions, with no guarantee on completion or terms. This initiative aims to support Relay's innovative drug discovery efforts using its Dynamo™ platform in oncology and genetic diseases.
Relay Therapeutics announced promising interim clinical data for RLY-4008, a selective FGFR2 inhibitor, presented at the AACR-NCI-EORTC Molecular Targets Conference. In a first-in-human trial, 80% of patients showed tumor shrinkage, with three of six cholangiocarcinoma patients achieving confirmed partial responses. The drug exhibited a favorable safety profile, with minimal off-target toxicities. Relay plans to finalize a recommended Phase 2 dose and expand cohorts by the end of 2021, indicating a strong potential market entry for this targeted therapy.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
What is Relay Therapeutics' primary focus?
Where is Relay Therapeutics headquartered?
What is the Dynamo™ platform?
What are some of Relay Therapeutics' key product candidates?
How financially stable is Relay Therapeutics?
Which significant partnerships has Relay Therapeutics established?
What recent progress has Relay Therapeutics made?
How does Relay Therapeutics plan to use its financial resources?
When was Relay Therapeutics founded?
What makes Relay Therapeutics' approach unique?
